JP2018522907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522907A5 JP2018522907A5 JP2018506346A JP2018506346A JP2018522907A5 JP 2018522907 A5 JP2018522907 A5 JP 2018522907A5 JP 2018506346 A JP2018506346 A JP 2018506346A JP 2018506346 A JP2018506346 A JP 2018506346A JP 2018522907 A5 JP2018522907 A5 JP 2018522907A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- chimeric antigen
- antigen receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570518 | 2015-08-11 | ||
| DKPA201570518 | 2015-08-11 | ||
| EPPCT/EP2016/051467 | 2016-01-25 | ||
| PCT/EP2016/051467 WO2016120216A1 (en) | 2015-01-26 | 2016-01-25 | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| PCT/EP2016/067800 WO2017025323A1 (en) | 2015-08-11 | 2016-07-26 | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522907A JP2018522907A (ja) | 2018-08-16 |
| JP2018522907A5 true JP2018522907A5 (https=) | 2019-07-25 |
Family
ID=53836344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506346A Withdrawn JP2018522907A (ja) | 2015-08-11 | 2016-07-26 | Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10709775B2 (https=) |
| EP (1) | EP3334442B1 (https=) |
| JP (1) | JP2018522907A (https=) |
| KR (1) | KR20180041152A (https=) |
| CN (1) | CN108495641A (https=) |
| AU (1) | AU2016307050A1 (https=) |
| BR (1) | BR112018002600A2 (https=) |
| CA (1) | CA2994746A1 (https=) |
| IL (1) | IL257009A (https=) |
| MX (1) | MX2018001776A (https=) |
| RU (1) | RU2018107754A (https=) |
| WO (1) | WO2017025323A1 (https=) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| WO2016075612A1 (en) * | 2014-11-12 | 2016-05-19 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| US10508143B1 (en) | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN109232742B (zh) * | 2017-07-11 | 2021-10-22 | 深圳市第二人民医院 | 一种嵌合抗原受体及其应用 |
| JP7410856B2 (ja) * | 2017-07-18 | 2024-01-10 | シーエスエル・ベーリング・ジーン・セラピー・インコーポレイテッド | ドナー改変細胞の選択のための調節可能スイッチ |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| EP3720882A4 (en) | 2017-12-05 | 2021-10-27 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE |
| EP3720883B1 (en) | 2017-12-05 | 2023-04-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| IL316257A (en) * | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| US20230158070A1 (en) * | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| CN112041432A (zh) * | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| KR102817092B1 (ko) | 2018-03-29 | 2025-06-09 | 페이트 세러퓨틱스, 인코포레이티드 | 조작된 면역 효과기 세포 및 이의 용도 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| KR20210044783A (ko) * | 2018-07-11 | 2021-04-23 | 모멘타 파머슈티컬스 인코포레이티드 | CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| MX2021000307A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| CN109293774B (zh) * | 2018-10-16 | 2021-05-28 | 南京医科大学 | 特异性结合cd19的全人源化抗体及应用 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| BR112021008041A2 (pt) * | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com células imunitárias anti-cd33 |
| CN119592592A (zh) * | 2018-11-30 | 2025-03-11 | 莱蒂恩技术公司 | 用于用抗cd38免疫治疗来治疗癌症的组合物和方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| AU2020299774A1 (en) | 2019-07-03 | 2022-01-20 | Peptidream Inc. | CD38-binding agents and uses thereof |
| EP3999540A1 (en) * | 2019-07-16 | 2022-05-25 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Antibodies having specificity for cd38 and uses thereof |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| US20230016034A1 (en) * | 2019-12-06 | 2023-01-19 | Fate Therapeutics, Inc. | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS |
| CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
| CN111484563B (zh) * | 2020-04-30 | 2020-11-10 | 徐州医科大学附属医院 | 一种抗cd38嵌合抗原受体及其应用 |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| JP2023541457A (ja) * | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| TWI905354B (zh) | 2020-12-31 | 2025-11-21 | 法商英耐特醫藥公司 | 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體 |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| JP2024540723A (ja) * | 2021-11-03 | 2024-11-01 | インテリア セラピューティクス，インコーポレーテッド | 免疫療法のためのｃｄ３８組成物及び方法 |
| KR20250017240A (ko) | 2022-05-27 | 2025-02-04 | 사노피 | FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자 |
| CA3261440A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics, Inc. | MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS |
| EP4583905A1 (en) * | 2022-09-06 | 2025-07-16 | Institut National de la Santé et de la Recherche Médicale | Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies |
| CA3267132A1 (en) * | 2022-09-09 | 2024-03-14 | Regents Of The University Of Minnesota | ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| JP2025074700A (ja) * | 2023-10-30 | 2025-05-14 | 学校法人藤田学園 | 抗ｃｄ３８－ｃａｒを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物 |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
| US20250262300A1 (en) * | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2026018922A1 (ja) * | 2024-07-19 | 2026-01-22 | 国立大学法人京都大学 | ＳＡＲＳ－ＣｏＶ－２感染症治療および／または予防用細胞及びその製法 |
| CN120349403A (zh) * | 2025-04-23 | 2025-07-22 | 河南农业大学 | 一种抗猪流行性腹泻病毒n蛋白的单克隆抗体及其识别的抗原表位肽和应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US9982251B2 (en) | 2003-03-14 | 2018-05-29 | Cellectis S.A. | Large volume ex vivo electroporation method |
| EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| EP1863909B2 (en) | 2005-03-15 | 2014-09-10 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| EP2877488B1 (en) | 2012-07-24 | 2021-02-24 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
| MX367730B (es) | 2012-09-04 | 2019-09-04 | Cellectis | Receptor de antigeno quimerico multi-cadena y usos del mismo. |
| AU2014266833B2 (en) * | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| FI2997141T3 (fi) | 2013-05-13 | 2022-12-15 | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
| WO2014191128A1 (en) * | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| PL3119807T3 (pl) | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| BR112017013981A2 (pt) * | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
-
2016
- 2016-07-26 WO PCT/EP2016/067800 patent/WO2017025323A1/en not_active Ceased
- 2016-07-26 KR KR1020187006555A patent/KR20180041152A/ko not_active Withdrawn
- 2016-07-26 RU RU2018107754A patent/RU2018107754A/ru not_active Application Discontinuation
- 2016-07-26 US US15/751,472 patent/US10709775B2/en active Active
- 2016-07-26 AU AU2016307050A patent/AU2016307050A1/en not_active Abandoned
- 2016-07-26 BR BR112018002600-0A patent/BR112018002600A2/pt not_active IP Right Cessation
- 2016-07-26 JP JP2018506346A patent/JP2018522907A/ja not_active Withdrawn
- 2016-07-26 CA CA2994746A patent/CA2994746A1/en not_active Abandoned
- 2016-07-26 MX MX2018001776A patent/MX2018001776A/es unknown
- 2016-07-26 EP EP16751219.3A patent/EP3334442B1/en active Active
- 2016-07-26 CN CN201680046216.9A patent/CN108495641A/zh active Pending
-
2018
- 2018-01-18 IL IL257009A patent/IL257009A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522907A5 (https=) | ||
| JP7682820B2 (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| AU2019222550B2 (en) | Modified pluripotent stem cells and methods of making and use | |
| EP1503794B9 (en) | Methods of treatement using ctla-4 antibodies | |
| RU2018107754A (ru) | Клетки для иммунотерапии, созданные для таргетинга антигена cd38 и для инактивации гена cd38 | |
| TWI807077B (zh) | 嵌合抗原受體療法t細胞擴增動力學及其用途 | |
| KR20210149049A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| US20260078163A1 (en) | T-cell receptor that targets egfr mutation and methods of using the same | |
| EP4714981A1 (en) | Immune effector cell and use thereof | |
| HK40069741A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40039113A (en) | Toxicity management for anti-tumor activity of cars | |
| EA041322B1 (ru) | Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car) |